Polivy adcom: no overall survival, no problem
A US adcom surprisingly backs Polivy’s front-line use, and blockbuster sales could follow.
US deal watchdog's bark could be worse than its bite
Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?
A year of two halves for US approvals
FDA green lights picked up in the second half, but for the really impressive number look at year-five sales.
Regulatory developments over the Christmas period
The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.
Illumina loses its grip
The sequencing giant’s acquisition of Grail is heading for the rocks.
An expensive new haemophilia gene therapy hits the US
The approval is good for CSL, and better for Uniqure.